Megadose clonazepam dependence: a case report. 2007

Arash Mowla, and Ali Firoozabadi, and Afshin Borhani Haghighi, and Ali Sahraian

UI MeSH Term Description Entries
D001883 Borderline Personality Disorder A personality disorder marked by a pattern of instability of interpersonal relationships, self-image, and affects, and marked impulsivity beginning by early adulthood and present in a variety of contexts. (DSM-IV) Personality Disorder, Borderline,Disorder, Borderline Personality,Borderline Personality Disorders,Disorders, Borderline Personality,Personality Disorders, Borderline
D002220 Carbamazepine A dibenzazepine that acts as a sodium channel blocker. It is used as an anticonvulsant for the treatment of grand mal and psychomotor or focal SEIZURES. It may also be used in the management of BIPOLAR DISORDER, and has analgesic properties. Amizepine,Carbamazepine Acetate,Carbamazepine Anhydrous,Carbamazepine Dihydrate,Carbamazepine Hydrochloride,Carbamazepine L-Tartrate (4:1),Carbamazepine Phosphate,Carbamazepine Sulfate (2:1),Carbazepin,Epitol,Finlepsin,Neurotol,Tegretol
D002998 Clonazepam An anticonvulsant used for several types of seizures, including myotonic or atonic seizures, photosensitive epilepsy, and absence seizures, although tolerance may develop. It is seldom effective in generalized tonic-clonic or partial seizures. The mechanism of action appears to involve the enhancement of GAMMA-AMINOBUTYRIC ACID receptor responses. 2H-1,4-Benzodiazepin-2-one, 5-(2-chlorophenyl)-1,3-dihydro-7-nitro-,Klonopin,Antelepsin,Rivotril,Ro 5-4023,Ro 54023
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D004361 Drug Tolerance Progressive diminution of the susceptibility of a human or animal to the effects of a drug, resulting from its continued administration. It should be differentiated from DRUG RESISTANCE wherein an organism, disease, or tissue fails to respond to the intended effectiveness of a chemical or drug. It should also be differentiated from MAXIMUM TOLERATED DOSE and NO-OBSERVED-ADVERSE-EFFECT LEVEL. Drug Tolerances,Tolerance, Drug,Tolerances, Drug
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000927 Anticonvulsants Drugs used to prevent SEIZURES or reduce their severity. Anticonvulsant,Anticonvulsant Drug,Anticonvulsive Agent,Anticonvulsive Drug,Antiepileptic,Antiepileptic Agent,Antiepileptic Agents,Antiepileptic Drug,Anticonvulsant Drugs,Anticonvulsive Agents,Anticonvulsive Drugs,Antiepileptic Drugs,Antiepileptics,Agent, Anticonvulsive,Agent, Antiepileptic,Agents, Anticonvulsive,Agents, Antiepileptic,Drug, Anticonvulsant,Drug, Anticonvulsive,Drug, Antiepileptic,Drugs, Anticonvulsant,Drugs, Anticonvulsive,Drugs, Antiepileptic
D013375 Substance Withdrawal Syndrome Physiological and psychological symptoms associated with withdrawal from the use of a drug after prolonged administration or habituation. The concept includes withdrawal from smoking or drinking, as well as withdrawal from an administered drug. Drug Withdrawal Symptoms,Withdrawal Symptoms,Drug Withdrawal Symptom,Substance Withdrawal Syndromes,Symptom, Drug Withdrawal,Symptom, Withdrawal,Symptoms, Drug Withdrawal,Symptoms, Withdrawal,Syndrome, Substance Withdrawal,Syndromes, Substance Withdrawal,Withdrawal Symptom,Withdrawal Symptom, Drug,Withdrawal Symptoms, Drug,Withdrawal Syndrome, Substance,Withdrawal Syndromes, Substance

Related Publications

Arash Mowla, and Ali Firoozabadi, and Afshin Borhani Haghighi, and Ali Sahraian
January 2013, Case reports in psychiatry,
Arash Mowla, and Ali Firoozabadi, and Afshin Borhani Haghighi, and Ali Sahraian
November 2003, Addiction (Abingdon, England),
Arash Mowla, and Ali Firoozabadi, and Afshin Borhani Haghighi, and Ali Sahraian
September 2016, Psychiatria Danubina,
Arash Mowla, and Ali Firoozabadi, and Afshin Borhani Haghighi, and Ali Sahraian
March 2016, Medicine,
Arash Mowla, and Ali Firoozabadi, and Afshin Borhani Haghighi, and Ali Sahraian
January 2008, The American journal on addictions,
Arash Mowla, and Ali Firoozabadi, and Afshin Borhani Haghighi, and Ali Sahraian
March 2021, BMC psychiatry,
Arash Mowla, and Ali Firoozabadi, and Afshin Borhani Haghighi, and Ali Sahraian
January 2021, Journal of the Academy of Consultation-Liaison Psychiatry,
Arash Mowla, and Ali Firoozabadi, and Afshin Borhani Haghighi, and Ali Sahraian
May 2024, Clinical case reports,
Arash Mowla, and Ali Firoozabadi, and Afshin Borhani Haghighi, and Ali Sahraian
January 2012, Wiadomosci lekarskie (Warsaw, Poland : 1960),
Arash Mowla, and Ali Firoozabadi, and Afshin Borhani Haghighi, and Ali Sahraian
January 1986, Pharmacology,
Copied contents to your clipboard!